Oral and anal vaccination confers full protection against enteric redmouth disease (ERM) in rainbow trout

PLoS One. 2014 Apr 4;9(4):e93845. doi: 10.1371/journal.pone.0093845. eCollection 2014.

Abstract

The effect of oral vaccines against bacterial fish diseases has been a topic for debate for decades. Recently both M-like cells and dendritic cells have been discovered in the intestine of rainbow trout. It is therefore likely that antigens reaching the intestine can be taken up and thereby induce immunity in orally vaccinated fish. The objective of this project was to investigate whether oral and anal vaccination of rainbow trout induces protection against an experimental waterborne infection with the pathogenic enterobacteria Yersinia ruckeri O1 biotype 1 the causative agent of enteric redmouth disease (ERM). Rainbow trout were orally vaccinated with AquaVac ERM Oral (MERCK Animal Health) or an experimental vaccine bacterin of Y. ruckeri O1. Both vaccines were tested with and without a booster vaccination four months post the primary vaccination. Furthermore, two groups of positive controls were included, one group receiving the experimental oral vaccine in a 50 times higher dose, and the other group receiving a single dose administered anally in order to bypass the stomach. Each group was bath challenged with 6.3 × 10(8) CFU/ml Y. ruckeri, six months post the primary vaccination. The challenge induced significant mortality in all the infected groups except for the groups vaccinated anally with a single dose or orally with the high dose of bacterin. Both of these groups had 100% survival. These results show that a low dose of Y. ruckeri bacterin induces full protection when the bacterin is administered anally. Oral vaccination also induces full protection, however, at a dose 50 times higher than if the fish were to be vaccinated anally. This indicates that much of the orally fed antigen is digested in the stomach before it reaches the second segment of the intestine where it can be taken up as immunogenic antigens and presented to lymphocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Administration, Rectal
  • Animals
  • Bacterial Vaccines / administration & dosage
  • Bacterial Vaccines / pharmacology*
  • Enzyme-Linked Immunosorbent Assay / veterinary
  • Fish Diseases / microbiology*
  • Fish Diseases / prevention & control*
  • Head Kidney / microbiology
  • Immunohistochemistry / veterinary
  • Oncorhynchus mykiss*
  • Treatment Outcome
  • Vaccination / veterinary*
  • Yersinia Infections / prevention & control
  • Yersinia Infections / veterinary*
  • Yersinia ruckeri / drug effects*

Substances

  • Bacterial Vaccines

Grants and funding

This work was funded by a Sapere Aude Grant 11-105095 from the Danish Research Council, entitled: “Understanding Key Mechanisms in Mucosal Immunity: Development of a New Immersion Vaccine”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.